Copyright Reports & Markets. All rights reserved.

Global Neuroblastoma Chemotherapy Drugs Market 2025 by Manufacturers, Regions, Type and Application, Forecast to 2031

Request for Sample of this report
Buy now

1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Market Analysis by Type
    • 1.3.1 Overview: Global Neuroblastoma Chemotherapy Drugs Consumption Value by Type: 2020 Versus 2024 Versus 2031
    • 1.3.2 Cyclophosphamide
    • 1.3.3 Cisplatin or Carboplatin
    • 1.3.4 Vincristine
    • 1.3.5 Doxorubicin (Adriamycin)
    • 1.3.6 Etoposide
    • 1.3.7 Other
  • 1.4 Market Analysis by Application
    • 1.4.1 Overview: Global Neuroblastoma Chemotherapy Drugs Consumption Value by Application: 2020 Versus 2024 Versus 2031
    • 1.4.2 Hospital
    • 1.4.3 Clinic
    • 1.4.4 Other
  • 1.5 Global Neuroblastoma Chemotherapy Drugs Market Size & Forecast
    • 1.5.1 Global Neuroblastoma Chemotherapy Drugs Consumption Value (2020 & 2024 & 2031)
    • 1.5.2 Global Neuroblastoma Chemotherapy Drugs Sales Quantity (2020-2031)
    • 1.5.3 Global Neuroblastoma Chemotherapy Drugs Average Price (2020-2031)

2 Manufacturers Profiles

  • 2.1 Baxter Healthcare
    • 2.1.1 Baxter Healthcare Details
    • 2.1.2 Baxter Healthcare Major Business
    • 2.1.3 Baxter Healthcare Neuroblastoma Chemotherapy Drugs Product and Services
    • 2.1.4 Baxter Healthcare Neuroblastoma Chemotherapy Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
    • 2.1.5 Baxter Healthcare Recent Developments/Updates
  • 2.2 Ingenus Pharmaceuticals
    • 2.2.1 Ingenus Pharmaceuticals Details
    • 2.2.2 Ingenus Pharmaceuticals Major Business
    • 2.2.3 Ingenus Pharmaceuticals Neuroblastoma Chemotherapy Drugs Product and Services
    • 2.2.4 Ingenus Pharmaceuticals Neuroblastoma Chemotherapy Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
    • 2.2.5 Ingenus Pharmaceuticals Recent Developments/Updates
  • 2.3 ANI Pharmaceuticals
    • 2.3.1 ANI Pharmaceuticals Details
    • 2.3.2 ANI Pharmaceuticals Major Business
    • 2.3.3 ANI Pharmaceuticals Neuroblastoma Chemotherapy Drugs Product and Services
    • 2.3.4 ANI Pharmaceuticals Neuroblastoma Chemotherapy Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
    • 2.3.5 ANI Pharmaceuticals Recent Developments/Updates
  • 2.4 Teva Pharmaceuticals
    • 2.4.1 Teva Pharmaceuticals Details
    • 2.4.2 Teva Pharmaceuticals Major Business
    • 2.4.3 Teva Pharmaceuticals Neuroblastoma Chemotherapy Drugs Product and Services
    • 2.4.4 Teva Pharmaceuticals Neuroblastoma Chemotherapy Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
    • 2.4.5 Teva Pharmaceuticals Recent Developments/Updates
  • 2.5 Qilu Pharmaceutical
    • 2.5.1 Qilu Pharmaceutical Details
    • 2.5.2 Qilu Pharmaceutical Major Business
    • 2.5.3 Qilu Pharmaceutical Neuroblastoma Chemotherapy Drugs Product and Services
    • 2.5.4 Qilu Pharmaceutical Neuroblastoma Chemotherapy Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
    • 2.5.5 Qilu Pharmaceutical Recent Developments/Updates
  • 2.6 Pfizer
    • 2.6.1 Pfizer Details
    • 2.6.2 Pfizer Major Business
    • 2.6.3 Pfizer Neuroblastoma Chemotherapy Drugs Product and Services
    • 2.6.4 Pfizer Neuroblastoma Chemotherapy Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
    • 2.6.5 Pfizer Recent Developments/Updates
  • 2.7 Hikma Pharmaceuticals
    • 2.7.1 Hikma Pharmaceuticals Details
    • 2.7.2 Hikma Pharmaceuticals Major Business
    • 2.7.3 Hikma Pharmaceuticals Neuroblastoma Chemotherapy Drugs Product and Services
    • 2.7.4 Hikma Pharmaceuticals Neuroblastoma Chemotherapy Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
    • 2.7.5 Hikma Pharmaceuticals Recent Developments/Updates
  • 2.8 Fresenius Kabi
    • 2.8.1 Fresenius Kabi Details
    • 2.8.2 Fresenius Kabi Major Business
    • 2.8.3 Fresenius Kabi Neuroblastoma Chemotherapy Drugs Product and Services
    • 2.8.4 Fresenius Kabi Neuroblastoma Chemotherapy Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
    • 2.8.5 Fresenius Kabi Recent Developments/Updates
  • 2.9 Accord Healthcare
    • 2.9.1 Accord Healthcare Details
    • 2.9.2 Accord Healthcare Major Business
    • 2.9.3 Accord Healthcare Neuroblastoma Chemotherapy Drugs Product and Services
    • 2.9.4 Accord Healthcare Neuroblastoma Chemotherapy Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
    • 2.9.5 Accord Healthcare Recent Developments/Updates
  • 2.10 Viatris
    • 2.10.1 Viatris Details
    • 2.10.2 Viatris Major Business
    • 2.10.3 Viatris Neuroblastoma Chemotherapy Drugs Product and Services
    • 2.10.4 Viatris Neuroblastoma Chemotherapy Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
    • 2.10.5 Viatris Recent Developments/Updates

3 Competitive Environment: Neuroblastoma Chemotherapy Drugs by Manufacturer

  • 3.1 Global Neuroblastoma Chemotherapy Drugs Sales Quantity by Manufacturer (2020-2025)
  • 3.2 Global Neuroblastoma Chemotherapy Drugs Revenue by Manufacturer (2020-2025)
  • 3.3 Global Neuroblastoma Chemotherapy Drugs Average Price by Manufacturer (2020-2025)
  • 3.4 Market Share Analysis (2024)
    • 3.4.1 Producer Shipments of Neuroblastoma Chemotherapy Drugs by Manufacturer Revenue ($MM) and Market Share (%): 2024
    • 3.4.2 Top 3 Neuroblastoma Chemotherapy Drugs Manufacturer Market Share in 2024
    • 3.4.3 Top 6 Neuroblastoma Chemotherapy Drugs Manufacturer Market Share in 2024
  • 3.5 Neuroblastoma Chemotherapy Drugs Market: Overall Company Footprint Analysis
    • 3.5.1 Neuroblastoma Chemotherapy Drugs Market: Region Footprint
    • 3.5.2 Neuroblastoma Chemotherapy Drugs Market: Company Product Type Footprint
    • 3.5.3 Neuroblastoma Chemotherapy Drugs Market: Company Product Application Footprint
  • 3.6 New Market Entrants and Barriers to Market Entry
  • 3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

  • 4.1 Global Neuroblastoma Chemotherapy Drugs Market Size by Region
    • 4.1.1 Global Neuroblastoma Chemotherapy Drugs Sales Quantity by Region (2020-2031)
    • 4.1.2 Global Neuroblastoma Chemotherapy Drugs Consumption Value by Region (2020-2031)
    • 4.1.3 Global Neuroblastoma Chemotherapy Drugs Average Price by Region (2020-2031)
  • 4.2 North America Neuroblastoma Chemotherapy Drugs Consumption Value (2020-2031)
  • 4.3 Europe Neuroblastoma Chemotherapy Drugs Consumption Value (2020-2031)
  • 4.4 Asia-Pacific Neuroblastoma Chemotherapy Drugs Consumption Value (2020-2031)
  • 4.5 South America Neuroblastoma Chemotherapy Drugs Consumption Value (2020-2031)
  • 4.6 Middle East & Africa Neuroblastoma Chemotherapy Drugs Consumption Value (2020-2031)

5 Market Segment by Type

  • 5.1 Global Neuroblastoma Chemotherapy Drugs Sales Quantity by Type (2020-2031)
  • 5.2 Global Neuroblastoma Chemotherapy Drugs Consumption Value by Type (2020-2031)
  • 5.3 Global Neuroblastoma Chemotherapy Drugs Average Price by Type (2020-2031)

6 Market Segment by Application

  • 6.1 Global Neuroblastoma Chemotherapy Drugs Sales Quantity by Application (2020-2031)
  • 6.2 Global Neuroblastoma Chemotherapy Drugs Consumption Value by Application (2020-2031)
  • 6.3 Global Neuroblastoma Chemotherapy Drugs Average Price by Application (2020-2031)

7 North America

  • 7.1 North America Neuroblastoma Chemotherapy Drugs Sales Quantity by Type (2020-2031)
  • 7.2 North America Neuroblastoma Chemotherapy Drugs Sales Quantity by Application (2020-2031)
  • 7.3 North America Neuroblastoma Chemotherapy Drugs Market Size by Country
    • 7.3.1 North America Neuroblastoma Chemotherapy Drugs Sales Quantity by Country (2020-2031)
    • 7.3.2 North America Neuroblastoma Chemotherapy Drugs Consumption Value by Country (2020-2031)
    • 7.3.3 United States Market Size and Forecast (2020-2031)
    • 7.3.4 Canada Market Size and Forecast (2020-2031)
    • 7.3.5 Mexico Market Size and Forecast (2020-2031)

8 Europe

  • 8.1 Europe Neuroblastoma Chemotherapy Drugs Sales Quantity by Type (2020-2031)
  • 8.2 Europe Neuroblastoma Chemotherapy Drugs Sales Quantity by Application (2020-2031)
  • 8.3 Europe Neuroblastoma Chemotherapy Drugs Market Size by Country
    • 8.3.1 Europe Neuroblastoma Chemotherapy Drugs Sales Quantity by Country (2020-2031)
    • 8.3.2 Europe Neuroblastoma Chemotherapy Drugs Consumption Value by Country (2020-2031)
    • 8.3.3 Germany Market Size and Forecast (2020-2031)
    • 8.3.4 France Market Size and Forecast (2020-2031)
    • 8.3.5 United Kingdom Market Size and Forecast (2020-2031)
    • 8.3.6 Russia Market Size and Forecast (2020-2031)
    • 8.3.7 Italy Market Size and Forecast (2020-2031)

9 Asia-Pacific

  • 9.1 Asia-Pacific Neuroblastoma Chemotherapy Drugs Sales Quantity by Type (2020-2031)
  • 9.2 Asia-Pacific Neuroblastoma Chemotherapy Drugs Sales Quantity by Application (2020-2031)
  • 9.3 Asia-Pacific Neuroblastoma Chemotherapy Drugs Market Size by Region
    • 9.3.1 Asia-Pacific Neuroblastoma Chemotherapy Drugs Sales Quantity by Region (2020-2031)
    • 9.3.2 Asia-Pacific Neuroblastoma Chemotherapy Drugs Consumption Value by Region (2020-2031)
    • 9.3.3 China Market Size and Forecast (2020-2031)
    • 9.3.4 Japan Market Size and Forecast (2020-2031)
    • 9.3.5 South Korea Market Size and Forecast (2020-2031)
    • 9.3.6 India Market Size and Forecast (2020-2031)
    • 9.3.7 Southeast Asia Market Size and Forecast (2020-2031)
    • 9.3.8 Australia Market Size and Forecast (2020-2031)

10 South America

  • 10.1 South America Neuroblastoma Chemotherapy Drugs Sales Quantity by Type (2020-2031)
  • 10.2 South America Neuroblastoma Chemotherapy Drugs Sales Quantity by Application (2020-2031)
  • 10.3 South America Neuroblastoma Chemotherapy Drugs Market Size by Country
    • 10.3.1 South America Neuroblastoma Chemotherapy Drugs Sales Quantity by Country (2020-2031)
    • 10.3.2 South America Neuroblastoma Chemotherapy Drugs Consumption Value by Country (2020-2031)
    • 10.3.3 Brazil Market Size and Forecast (2020-2031)
    • 10.3.4 Argentina Market Size and Forecast (2020-2031)

11 Middle East & Africa

  • 11.1 Middle East & Africa Neuroblastoma Chemotherapy Drugs Sales Quantity by Type (2020-2031)
  • 11.2 Middle East & Africa Neuroblastoma Chemotherapy Drugs Sales Quantity by Application (2020-2031)
  • 11.3 Middle East & Africa Neuroblastoma Chemotherapy Drugs Market Size by Country
    • 11.3.1 Middle East & Africa Neuroblastoma Chemotherapy Drugs Sales Quantity by Country (2020-2031)
    • 11.3.2 Middle East & Africa Neuroblastoma Chemotherapy Drugs Consumption Value by Country (2020-2031)
    • 11.3.3 Turkey Market Size and Forecast (2020-2031)
    • 11.3.4 Egypt Market Size and Forecast (2020-2031)
    • 11.3.5 Saudi Arabia Market Size and Forecast (2020-2031)
    • 11.3.6 South Africa Market Size and Forecast (2020-2031)

12 Market Dynamics

  • 12.1 Neuroblastoma Chemotherapy Drugs Market Drivers
  • 12.2 Neuroblastoma Chemotherapy Drugs Market Restraints
  • 12.3 Neuroblastoma Chemotherapy Drugs Trends Analysis
  • 12.4 Porters Five Forces Analysis
    • 12.4.1 Threat of New Entrants
    • 12.4.2 Bargaining Power of Suppliers
    • 12.4.3 Bargaining Power of Buyers
    • 12.4.4 Threat of Substitutes
    • 12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain

  • 13.1 Raw Material of Neuroblastoma Chemotherapy Drugs and Key Manufacturers
  • 13.2 Manufacturing Costs Percentage of Neuroblastoma Chemotherapy Drugs
  • 13.3 Neuroblastoma Chemotherapy Drugs Production Process
  • 13.4 Industry Value Chain Analysis

14 Shipments by Distribution Channel

  • 14.1 Sales Channel
    • 14.1.1 Direct to End-User
    • 14.1.2 Distributors
  • 14.2 Neuroblastoma Chemotherapy Drugs Typical Distributors
  • 14.3 Neuroblastoma Chemotherapy Drugs Typical Customers

15 Research Findings and Conclusion

    16 Appendix

    • 16.1 Methodology
    • 16.2 Research Process and Data Source

    According to our (Global Info Research) latest study, the global Neuroblastoma Chemotherapy Drugs market size was valued at US$ million in 2024 and is forecast to a readjusted size of USD million by 2031 with a CAGR of %during review period.
    Chemotherapy (chemo) is the use of anti-cancer drugs, which are usually given into a vein. The drugs enter the bloodstream and travel throughout the body to reach and destroy cancer cells. This makes chemo useful for treating neuroblastoma, especially if it can"t all be removed with surgery. The most common combination of drugs includes cisplatin (or carboplatin), cyclophosphamide, doxorubicin, vincristine, and etoposide, but others may be used.
    The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
    Neuroblastoma, a common malignant tumor in children, relies significantly on chemotherapy as part of its comprehensive treatment. Several chemotherapy drugs targeting neuroblastoma are already available in the market, effectively controlling disease progression by interfering with the growth and division of tumor cells. The market size has been gradually expanding due to increasing diagnosis rates and advancements in medical technology, leading to consistent growth in sales of chemotherapy drugs for pediatric neuroblastoma. Looking ahead, with the development of personalized treatments and targeted therapies, neuroblastoma chemotherapy drugs are poised to become more precise in targeting tumor cells, minimizing side effects, and enhancing therapeutic efficacy, thereby offering greater hope for affected children.
    This report is a detailed and comprehensive analysis for global Neuroblastoma Chemotherapy Drugs market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
    Key Features:
    Global Neuroblastoma Chemotherapy Drugs market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031
    Global Neuroblastoma Chemotherapy Drugs market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031
    Global Neuroblastoma Chemotherapy Drugs market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031
    Global Neuroblastoma Chemotherapy Drugs market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2020-2025
    The Primary Objectives in This Report Are:
    To determine the size of the total market opportunity of global and key countries
    To assess the growth potential for Neuroblastoma Chemotherapy Drugs
    To forecast future growth in each product and end-use market
    To assess competitive factors affecting the marketplace
    This report profiles key players in the global Neuroblastoma Chemotherapy Drugs market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Baxter Healthcare, Ingenus Pharmaceuticals, ANI Pharmaceuticals, Teva Pharmaceuticals, Qilu Pharmaceutical, Pfizer, Hikma Pharmaceuticals, Fresenius Kabi, Accord Healthcare, Viatris, etc.
    This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
    Market Segmentation
    Neuroblastoma Chemotherapy Drugs market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
    Market segment by Type
    Cyclophosphamide
    Cisplatin or Carboplatin
    Vincristine
    Doxorubicin (Adriamycin)
    Etoposide
    Other
    Market segment by Application
    Hospital
    Clinic
    Other
    Major players covered
    Baxter Healthcare
    Ingenus Pharmaceuticals
    ANI Pharmaceuticals
    Teva Pharmaceuticals
    Qilu Pharmaceutical
    Pfizer
    Hikma Pharmaceuticals
    Fresenius Kabi
    Accord Healthcare
    Viatris
    Market segment by region, regional analysis covers
    North America (United States, Canada, and Mexico)
    Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
    South America (Brazil, Argentina, Colombia, and Rest of South America)
    Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 15 chapters:
    Chapter 1, to describe Neuroblastoma Chemotherapy Drugs product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top manufacturers of Neuroblastoma Chemotherapy Drugs, with price, sales quantity, revenue, and global market share of Neuroblastoma Chemotherapy Drugs from 2020 to 2025.
    Chapter 3, the Neuroblastoma Chemotherapy Drugs competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
    Chapter 4, the Neuroblastoma Chemotherapy Drugs breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2020 to 2031.
    Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2020 to 2031.
    Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2020 to 2025.and Neuroblastoma Chemotherapy Drugs market forecast, by regions, by Type, and by Application, with sales and revenue, from 2026 to 2031.
    Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
    Chapter 13, the key raw materials and key suppliers, and industry chain of Neuroblastoma Chemotherapy Drugs.
    Chapter 14 and 15, to describe Neuroblastoma Chemotherapy Drugs sales channel, distributors, customers, research findings and conclusion.

    Buy now